CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,378,206
- in 4 filings, $15.4M under 10b5-1 plans
Net −$15,378,206. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-14 | Arbuckle Stuart A EVP, COO | Sale | −2,003 | $299.13 | $599K | 77,739 |
| 2023-02-14 | Arbuckle Stuart A EVP, COO | Sale | −1,734 | $300.09 | $520K | 76,005 |
| 2023-02-14 | Arbuckle Stuart A EVP, COO | Sale | −400 | $300.89 | $120K | 75,605 |
| 2023-02-14 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −800 | $295.79 | $237K | 53,596 |
| 2023-02-14 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −842 | $296.85 | $250K | 52,754 |
| 2023-02-14 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −395 | $297.97 | $118K | 52,359 |
| 2023-02-14 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −2,165 | $299.08 | $648K | 50,194 |
| 2023-02-14 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −1,888 | $300.11 | $567K | 48,306 |
| 2023-02-14 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −308 | $301.02 | $93K | 47,998 |
| 2023-02-13 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Shares withheld for taxes | −4,992 | $298.26 | $1.5M | 65,191 |
| 2023-02-13 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Shares withheld for taxes | −2,995 | $298.26 | $893K | 66,040 |
| 2023-02-13 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −2 | $295.84 | $592 | 66,038 |
| 2023-02-13 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −78 | $298.11 | $23K | 65,960 |
| 2023-02-13 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −120 | $298.98 | $36K | 65,840 |
| 2023-02-13 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −64 | $299.88 | $19K | 65,776 |
| 2023-02-13 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −11 | $300.79 | $3K | 65,765 |
| 2023-02-13 | Sanna Bastiano EVP, Cell & Genetic Therapies | Shares withheld for taxes | −4,340 | $298.26 | $1.3M | 62,028 |
| 2023-02-13 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale | −113 | $300.39 | $34K | 61,915 |
| 2023-02-13 | Sachdev Amit EVP, Chief Patient Officer | Shares withheld for taxes | −4,657 | $298.26 | $1.4M | 72,484 |
| 2023-02-13 | LEIDEN JEFFREY M Executive Chairman | Shares withheld for taxes | −13,344 | $298.26 | $4.0M | 62,079 |
Page 36 of 40 · 781 trades